AIMD.P AIM4 Ventures

Annovis Bio to Present at the 2020 BIO Investor Forum

Annovis Bio to Present at the 2020 BIO Investor Forum
EN
12/10/2020

Underlying

AIMD.PAIM4 Ventures

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Achieves Significant Milestones and Sustains Strong Progress i...

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete, keeping Annovis on track for data readout MALVERN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) an...

November 6, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces $3.4 Million Registered Direct Offering of Common St...

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, the Company’...

October 27, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Closing of $6 Million Registered Direct Offering of ...

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per...

October 15, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces $6 Million Registered Direct Offering of Common Stoc...

Annovis Announces $6 Million Registered Direct Offering of Common Stock MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant i...

October 10, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Support...

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifyin...

October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch